Enterome and Gustave Roussy Enter into a Microbiome-Based Collaboration to Develop Novel Immunotherapy Solutions to Treat Cancer

PARIS--()--Enterome Bioscience SA, pioneer in the development of therapeutic solutions (drugs and diagnostics) based on the gut microbiome, announces that it has entered into a collaborative development agreement with Gustave Roussy, Europe's first comprehensive cancer centre.

An ambitious objective: The development of a new generation of drugs and non-invasive monitoring tools of the gut microbiome in immuno-oncology.

Professor Alexander Eggermont, CEO of Gustave Roussy, said. "We are convinced that Enterome's unique human microbiome platform and its expertise in understanding the links between the gut microbiome composition and the development of diseases, combined with our world-leading research in immuno-oncology, will allow the development of novel drugs and diagnostics that could extend the range of personalized treatment options for patients with cancer."

Collaboration with Gustave Roussy is based around Enterome's unique metagenomic technology platform that provides a deep understanding of the gut microbiome composition: a key new element in determining how effective cancer immunotherapies are and in identifying personalized ways to boost immune response against tumours. "Still a largely unexplored field, the gut microbiome offers numerous promising avenues for research that may soon lead to a shift to a new treatment paradigm in oncology," says Enterome CEO Pierre Bélichard.

This perspective is shared by Gustave Roussy's Tumour and Immunotherapy team which, thanks to progress made in understanding cellular and molecular tumour immunology over the last two decades, has identified new and innovative ways of manipulating the immune response to cancer promising much improved treatments outcome for patients with malignant tumours.

Team director Professor Laurence Zitvogel recently highlighted in Science the crucial role of gut microbiome in eliciting innate and adaptive immune responses beneficial for the host in relation to effective therapies against cancer (chemotherapies, immunotherapy based on immune checkpoint blockers).

Enterome's understanding of the microbiome space and Gustave Roussy's extensive development capabilities in the immune-oncology sphere combine to create a complementary partnership that today offers a unique opportunity to co-develop the new generation of cancer drugs.

About Enterome

Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as inflammatory bowel diseases, cancer, and metabolic diseases.

www.enterome.com

About Institut Gustave Roussy:

Gustave Roussy is the leading Cancer Centre in Europe – www.gustaveroussy.fr/en – http://www.gustaveroussy.fr/manifesto-cancerinnovation/

Contacts

Enterome media
Yucatan
Caroline Prince, +33-1-53-63-27-35
[email protected]

 

Sponsored By Parexel

Is your FSP vision 2020?

At Parexel, we get the right people to you, so you can get the right treatment to your patients. Our functional service provider (FSP) outsourcing has evolved with biopharma’s changing needs, so sponsors can efficiently manage staff and operations through resource flexibility, access to experts and technology and reduced labor costs. Our latest whitepaper discusses the current FSP models and provides expert tips for choosing the right one.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.